Manufacturing Services

Nanoform Taps Global CDMO to Accelerate Supply of Nanoformed Biologics 

By TPN Editorial TeamNovember 18, 2026
Nanoform Taps Global CDMO to Accelerate Supply of Nanoformed Biologics 
Sign in to save article

By partnering with a leading global CDMO, Nanoform is establishing an accelerated pathway to clinical and commercial manufacturing for its innovative nanoparticle suspension formulations.

Sanner

Medicine performance-enhancing company, Nanoform, has signed an agreement with a global CDMO partner to manufacture ultra-high-concentration biologics under good manufacturing practice (GMP) standards. According to Nanoform, the agreement, which was announced in a Nov. 17, 2026 press release (1), is an important step in progressing its biologics technology toward clinical application.

Under the terms of the agreement, the companies will establish a dedicated production line for Nanoform’s biologics technology within the CDMO’s aseptic manufacturing facility located in Germany. The chosen facility already has the capabilities in place to manufacture injectable biologics under GMP standards, including aseptic processing and fill/finish.

“We are pleased to have identified an excellent partner to enable us to accelerate our customers’ entry to clinic with subcutaneous ultra-high concentration suspension products enabled by nanoforming,” said Edward Hæggström, Chief Executive Officer of Nanoform, in a company press release. “We look forward to the implementation work at the partner’s site during the coming months. Both we and our customers are impressed by the expertise and speed by which this cooperation has started.”

The collaboration will offer Nanoform customers an accelerated pathway from formulation and preclinical development at Nanoform through to GMP manufacture and supply of material for clinical trials and later-stage commercial manufacturing. An accelerated transition into clinical development will be made possible through the combination of Nanoform’s biologics technology and development capabilities with the established aseptic infrastructure, quality systems, and manufacturing expertise of the CDMO partner (1)

“Enabling clinical supply is fundamental for our customers and partners also on the biologics side. The partnership announced today will provide an accelerated pathway to clinical supply of GMP material with a CDMO partner that is a global leader in aseptic manufacturing and has a strong network to support our joint customers,” added Christian Jones, Chief Commercial Officer of Nanoform, in the press release (1). “Nanoform believes subcutaneous delivery will become the dominant standard for new and marketed biologics. Nanoform’s suspension formulations enable high drug concentrations with particle properties that are critical for suspension performance.”

GMP readiness is targeted to be achieved in the second half of 2027, when it will be used to support a planned first customer clinical trial of a subcutaneous ultra-high concentration suspension biologic product enabled by nanoforming. 

No immediate material financial effect will be experienced by Nanoform as a result of this agreement.

Reference

1. Nanoform. Inside Information: Nanoform Selects Global CDMO Partner for GMP Manufacturing of Ultra-High-Concentration Biologics. Press Release, Nov. 17, 2026.

Sanner